BRAF V600E Expression by Immunohistochemistry in Colon Cancer and Clinico-pathologic Features Associated with BRAF-Mutated Colonic Cancers in Mexican Patients.

Karla J González-ColungaLeonardo Saúl Lino-SilvaRosa A Salcedo-HernándezErika B Ruiz-GarcíaCésar Zepeda-Najar

Published in: Journal of gastrointestinal cancer (2020)

IHC against BRAF V600E showed an excellent performance, making it feasible as an alternative for molecular examination. Tumors with BRAF mutated did not show distinctive clinico-pathological characteristics, except for a larger tumor size.

Keyphrases

wild type
metastatic colorectal cancer
end stage renal disease
ejection fraction
newly diagnosed
poor prognosis
prognostic factors
neoadjuvant chemotherapy
patient reported outcomes
binding protein